Hypercholesterolemia and 27-Hydroxycholesterol Increase S100A8 and RAGE Expression in the Brain: a Link Between Cholesterol, Alarmins, and Neurodegeneration

Raúl Loera-Valencia1,2 · Muhammad-Al-Mustafa Ismail1 · Julen Goikolea1 · Maria Lodeiro1 · Laura Mateos1 · Ingemar Björkhem2 · Elena Puerta1,3 · Mariana A. Romão4,5 · Cláudio M. Gomes4,5 · Paula Merino-Serrais1,6,7 · Silvia Maioli1 · Angel Cedazo-Minguez1

Received: 30 April 2021 / Accepted: 4 August 2021 / Published online: 27 August 2021
© The Author(s) 2021

Abstract
Alterations in cholesterol metabolism in the brain have a major role in the physiology of Alzheimer’s disease (AD). Oxysterols are cholesterol metabolites with multiple implications in memory functions and in neurodegeneration. Previous studies have shown detrimental effects of cholesterol metabolites in neurons, but its effect in glial cells is unknown. We used a high-fat/high-cholesterol diet in mice to study the effects of hypercholesterolemia over the alarmin S100A8 cascade in the hippocampus. Using CYP27Tg, a transgenic mouse model, we show that the hypercholesterolemia influence on the brain is mediated by the excess of 27-hydroxycholesterol (27-OH), a cholesterol metabolite. We also employed an acute model of 27-OH intraventricular injection in the brain to study RAGE and S100A8 response. We used primary cultures of neurons and astrocytes to study the effect of high levels of 27-OH over the S100A8 alarmin cascade. We report that a high-fat/high-cholesterol diet leads to an increase in S100A8 production in the brain. In CYP27Tg, we report an increase of S100A8 and its receptor RAGE in the hippocampus under elevated 27-OH in the brain. Using siRNA, we found that 27-OH upregulation of RAGE in astrocytes and neurons is mediated by the nuclear receptor RXRγ. Silencing RXRγ in neurons prevented 27-OH-mediated upregulation of RAGE. These results show that S100A8 alarmin and RAGE respond to high levels of 27-OH in the brain in both neurons and astrocytes through RXRγ. Our study supports the notion that 27-OH mediates detrimental effects of hypercholesterolemia to the brain via alarmin signaling.

Keywords Alarmins · Astrocytes · Retinoid receptors · Oxysterols · Alzheimer’s disease · Sterile inflammation

Background
Alzheimer’s disease (AD) is strongly associated with elevated circulating cholesterol during mid-life [1–5]. GWAS have identified risk genes involved in cholesterol metabolism in the brain including apolipoprotein E, allele epsilon 4 (APOEε4), clusterin (ApoJ), and the ATP binding cassette subfamily A member 7 (ABCA7) [6–9]. Nevertheless, cholesterol itself does not cross the blood–brain barrier (BBB), posing the question of how plasma hypercholesterolemia is linked to the risk of developing AD. Moreover, cholesterol-lowering therapies do not have a clear effect improving cognition of AD patients [10–12]. Unlike cholesterol, its side-chain oxidized metabolite, 27-hydroxycholesterol (27-OH), is able to traverse the BBB and correlates directly to circulating cholesterol levels in plasma in humans [13].

We have reported alterations in cognition observed in mice on a high-fat diet (HFD) [14] as well as in the chronically high 27-OH transgenic mice, CYP27A1 overexpressor (CYP27Tg) [15], suggesting that 27-OH may be mediated some of the deleterious effects of high peripheric cholesterol in the brain [16]. In support of this, we have shown that 27-OH affects the levels of the activity-regulated cytoskeleton-associated protein (Arc), a protein involved in long-term consolidation of memory [16].

27-OH have a proinflammatory role in atherosclerosis, being the most abundant oxysterol in atherosclerotic plaques
[17]. Whether 27-OH mediates inflammation in the brain is yet not known; however, AD patients exhibit higher levels of this oxysterol in their brains and cerebrospinal fluid (CSF) [18], and inflammation is considered an important feature of AD [19].

Sterile inflammation describes a response not triggered by microbial agents but by endogenous molecules called alarmins that are released during tissue damage [20]. A number of alarmins are increased in the AD brain, including S100 calcium-binding proteins [21, 22]. We have recently reported that there is a positive feedback between Aβ and S100A8 productions in brain cells and that mice overexpressing the precursor of Aβ accumulate S100A8 aggregates in the brain prior to the appearance of Aβ plaques [23]. Furthermore, S100A8 is one of the ligands of the receptor for advanced glycation end product (RAGE) [24], expressed in almost all brain cells including microglia, neurons, and astrocytes [25, 26]. Activation of RAGE is involved in inflammatory responses, promoting synaptic dysfunction and neurodegeneration [27].

Here, we investigate the effects of a high-cholesterol diet and 27-OH on S100A8 and RAGE in the brain. Utilizing several in vivo models, primary cultures of glial cells, and neurons treated with 27-OH, we report that 27-OH increases S100A8 and RAGE levels in the brain. Most interestingly, 27-OH mediates these effects involving the retinoid X receptor gamma (RXRγ) receptor in astrocytes and neurons, while activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκ-B) is also shown.

Methods

Animals

Five-to-six-week-old (C57BL/6) mice were obtained from B&K (Sollentuna, Sweden). The mice were grouped based on diet into two groups, normal chow diet (ND) or a high-fat diet (HFD) containing 21% fat and 0.15% cholesterol (R638, Lactamine, Sweden) for 9 months. Generation and breeding of the CYP27Tg mice have been described previously [28]. These mice were kept under controlled conditions of humidity and temperature on a 12-h light–dark cycle. Food and water were provided ad libitum. Animals were sacrificed by decapitation, and the brains immediately frozen on dry ice and stored at −80 °C. All procedures involving animals were conducted in accordance with the European regulation and approved by the Swedish Board of Agriculture (ethical permits ID S33-13, extension 57–15 and 4884/2019). All efforts were made to minimize suffering or distress to experimental animals.

Stereotaxic Injections

C57BL/6 mice were anesthetized with an isoflurane/oxygen mixture while being fixated on a stereotaxic frame (David Kopf Instruments) and placed on a heated pad at 37 °C to maintain normal body temperature. The lateral ventricle was injected bilaterally with 1 μl of solution per injection site, using a Hamilton syringe (10 μl gauge). The coordinates were set according to the Paxinos Mouse brain atlas and were 2.0 mm from the skull surface, −0.9 mm anteroposterior, and ±1.4 mm laterally from the bregma. The injection solution is composed of high-density lipoprotein (HDL) associated to 27-OH diluted in artificial CSF (aCSF) (RD Systems, 3525) and used at a final concentration of 10 μM. HDL diluted in aCSF was used for the control group. Incubation of 27-OH at a concentration ratio of 1:3 with HDL (Abcam, ab77881) at 37 °C for 1 h was done to produce the HDL-associated 27-OH.

Cell Cultures and Treatments

Cerebellar tissue from 18-day-old Sprague–Dawley rat embryos was dissected. Cerebellar tissue was dissociated and seeded in Dulbecco's Modified Eagle Medium (DMEM/F12) (Life Technologies, CA, USA) supplemented with 10% inactivated fetal bovine serum (FBS) (Life Technologies, CA, USA) in T75 plastic culture flasks (Corning, NY, USA). Cultures were incubated at 37 °C, 95% air/5% CO2, and culture media were replaced biweekly. Inactivated astrocyte-dominated cultures at 10–14 days were used as previously identified by immunocytochemical characterization [29]. 27-OH was obtained from Steraloids (Newport, Rhode Island, USA). Treatments were done after a 24 h period of being cultured in serum-free media and treated with 27-OH at a concentration of 1 μM for 24 h. Preincubation with 22(S)-hydroxycholesterol (22(S)-OH, 10 μM), a liver-X-receptor (LXR) inhibitor, was 3 h. Murine S100A8 was expressed in E. coli BL21(DE3) and purified to homogeneity using previously established protocols [30, 31] and quantitated using reported extinction coefficients [32]. Ethical consent for experiments with primary cultures was received from the regional ethical committee of Karolinska Institutet and by the Swedish Board of Agriculture (ethical permits ID S33-13, extension 57–15 and 4884/2019).

Human SH-SY5Y (ATCC® CRL-2266™) neuroblastoma cells were obtained from the American Type Culture Collection (ATCC) and cultured in a 1:1 mixture of DMEM/F-12 media and supplemented with 10% fetal
bovine serum in T75 plastic culture flasks (Corning, NY, USA) at 37 °C, with 5% CO2. For treatments, cells were seeded in 6-well plates and when confluent treated with 27-OH at 10 µM for 24 h. The nuclear and cytoplasmic extraction reagent kit NE-PER (Pierce, Rockford, IL, USA) was used to isolate the nuclear and cytosolic fractions of SH-SY5Y cells following the manufacturer’s protocol. Protease inhibitor cocktail (1:500, Sigma-Aldrich) was added freshly prepared. To quantify, immunoblotting against the nuclear marker Lamin-A/C was performed (Sigma-Aldrich SAB4200236, 1:1000).

Small Interference RNA Transfection

Astrocytes  RXRγ knockdown was performed using siRNA designed by Dharmacon (ON-TARGET plus SMARTpool; L-083061–02-0020). Rat primary astrocytes (80% confluence) were transfected with a final concentration of 25 nM per well and 4 µl of DharmaFECT 3 reagent (Dharmacon) according to the manufacturer’s instructions. The efficiency of the knockdown was evaluated using mRNA levels of RXRγ.

Neurons The same siRNA reagent was used for RXRγ knockdown in neurons (ON-TARGET plus SMARTpool; L-083061–02-0020). Rat primary neurons (80% confluence) at 5DIV were transfected with 25 nM per well and 4 µl of DharmaFECT 3 reagent (Dharmacon) according to the manufacturer’s instructions. After 72 h, the media was replaced for media containing the different treatments of vehicle and 27-OH 1 µM, which remained 24 h before collection. The efficiency of the knockdown was evaluated using mRNA levels of RXRγ.

RNA Extraction and Real-Time RT-PCR

RNA extraction and real-time PCR were performed as previously described [33]. Briefly, total RNA was extracted using the RNeasy lipid tissue mini kit from Qiagen (Palo Alto, CA, USA) following the manufacturer’s instructions. Real-time PCR amplification assay for target genes was performed with a total volume of 20 µl in each well containing 10 µl of PCR Master Mix (Life Technologies, CA, USA), 2 µl of cDNA corresponding to 10 ng of RNA, and 1 µl of each TaqMan Gene Expression Assays. Relative quantification of the target genes was done using the comparative cycle threshold method, 2−ΔΔCT, where ΔΔCT = (CTtarget gene − CCTarget GAPDHuntreated) − (Ctgtarget gene − CtgTarget GAPDHtreated). After the 2−ΔΔCT calculations of cDNA for every sample in triplicates, expression was portrayed as a mean ± SEM.

Immunohistochemistry

Immunohistochemistry was performed on coronal sections of fresh frozen brains from the hippocampus of the wild-type ND and HFD mice. The sections were fixed in cold 4% paraformaldehyde (PFA) in saline phosphate buffer (PBS, 0.1 M, pH 7.4) for 15 min and subsequently washed three times with PBS. After fixation, single immunohistochemistry was performed. All slices were blocked for 1 h in PBS with 0.25% Triton-X and 3% BSA. The sections were incubated overnight with the primary antibody goat anti-S100A8 (1:100; sc-48352, Santa Cruz) and then for 2 h at room temperature with the secondary antibody Alexa Fluor 594 donkey anti-goat. 4,6-Diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO, USA) was used to identify the nuclei of cell bodies. Finally, the sections were rinsed in PBS and mounted using the fluorescence mounting medium ProLong Gold antifade reagent (Invitrogen Corporation, Carlsbad, CA, USA). The sections were thoroughly washed in PBS throughout the various stages. The primary antibody was omitted with regard to the negative control.

Immunocytochemistry was performed on glial cells from primary cultures. The cells were seeded at 50% confluence onto cover slips. Following 24 h in serum-free media, the treatments were done, and then cells were pre-fixed with 2% PFA for 2 min and fixed with 4% PFA for 20 min. Afterwards, cells were washed three times with PBS. All cover slips were blocked for 30 min in PBS with 0.1% Triton-X and 1% BSA. The primary antibodies used were goat anti-S100A8 (1:100; sc-48352, Santa Cruz) and rabbit anti-RAGE (1:100; ab3611, Abcam). The secondary antibodies used were Alexa Fluor 594 donkey anti-goat and Alexa Fluor 488 chicken anti-rabbit, respectively. Cover slips were first incubated overnight with the primary antibodies and then for 30 min at room temperature with secondary antibodies and DAPI to identify the nuclei of cell bodies. Finally rinsed in PBS, the cover slips were mounted as described above. Between the different steps, the cover slips were thoroughly washed in PBS. Again, omission of the primary antibody indicates the negative control.

Confocal imaging was performed with a Zeiss LSM 510 META confocal laser scanning system. The fluorescence of DAPI, Alexa 594, and Alexa 488 was recorded through separate channels with either Plan Apo 40× dry (NA, 0.95) or 63× oil (NA, 1.3) lenses.

Cresyl Violet Staining

Fast cresyl violet staining was done to visualize the granules found in the corpora amylacea in the same sections used for immunohistochemistry. In brief, after the image processing, the sections were stained for 10 min with cresyl violet solution. Following staining, the sections
were dehydrated and cleared with xylene. Images were taken with an optical microscope (Nikon eclipse E800M) at 20× (NA, 0.75) under bright field optics.

**Western Blot and Densitometry Analysis**

Immunoblotting was carried out in mice hippocampal tissues and primary rat culture in addition to the neuroblastoma cell line. Tissue homogenization and immunoblotting were performed as previously described [34]. The following primary antibodies were used: goat anti-S100A8 (sc-48352, Santa Cruz), rabbit anti-RAGE (ab3611, Abcam), rabbit anti-RXRγ (ab15518, Abcam), rabbit anti-NFk-B (PA1-186, Thermo Fischer), rabbit anti-actin (A2103, Sigma), and mouse anti-Lamin AC (SAB4200236, Sigma). Primary antibody incubation was followed by the incubation with the respective secondary immunoglobulin G (IgG) at 1:3000–5000 dilutions (Amersham Biosciences). Immunoreactivity was detected using the ECL detection system (Amersham Biosciences). The relative density of the immunoreactive bands was calculated from the optical density multiplied by the area of the selected band using the ImageJ 1.383 software (NIH, MA).

**Statistical Analysis**

Data values are expressed as mean ± standard error mean (SEM). One-way ANOVA was used to compare differences between mean levels of variables among different groups, followed by Tukey’s post hoc test to compare means of every group between each other or Dunnett’s multiple comparisons to compare to the mean of a control group. Multiplicity adjusted P values are shown for multiple comparisons. Otherwise, unpaired t test or Mann–Whitney test was used. A P value of less than 0.05 was considered statistically significant.

**Results**

**High-Fat/High-Cholesterol Diet Enhances the Expression of S100A8 in the Brain**

S100A8 expression was analyzed in the hippocampus of wild-type mice (WT) fed with HFD (WT-HFD) compared to a normal diet (WT-ND) through immunohistochemical analysis. Figure 1A shows an increase in S100A8 immunoreactivity in the brain of WT-HFD compared to WT-ND (insets a and b). This increase appears as extracellular granular aggregates in the stratum oriens and stratum radiatum of the hippocampus.

![Fig. 1](image_url)

*Fig. 1* High-fat/high-cholesterol diet (HFD) and 27-OH enhance the expression of S100A8 in vivo. A Confocal microscopy of sections double stained with anti-S100A8 (red) and DAPI (blue) from the same field in the CA1 hippocampal region of WT mice on a normal diet (WT-ND) (a) or a high-fat diet (WT-HFD) (b). In c, the same section as b stained with cresyl violet showing, with an arrow, the S100A8 aggregates. Scale bar in c, 120 μm. B S100A8 mRNA expression levels in the hippocampus of WT-ND (*mean* = 1.34, *SEM* = 0.37, *n* = 8 animals) and WT-HFD (*mean* = 4.038, *SEM* = 1.22, *n* = 7 animals, *P* = 0.04). C A representative western blot showing protein levels of S100A8 of ND mice (*mean* = 100.0, *SEM* = 4.077, *n* = 4 animals) and HFD mice (*mean* = 142.8, *SEM* = 11.42, *n* = 4 animals, *P* = 0.012)
the hippocampus (Fig. 1A, inset b), areas of importance for learning and memory processes.

Members of the S100 protein family tend to aggregate and be part of the corpora amylacea (CA), which is found during the course of normal aging in the human brain [35]. Consistent with the accumulation of S100A8 seen in AD mouse models [23], cresyl violet staining revealed no overlap between the CA and the S100A8 aggregates (Fig. 1A, insets b vs. c).

Real-time PCR analysis of hippocampal samples from WT-HFD also showed an increase in S100A8 expression compared to WT-ND (Fig. 1B). By western blot, we confirmed that HFD induced increase of S100A8 in the hippocampus of mice (Fig. 1C).

27-OH Increases S100A8 and RAGE Expression In Vivo

Previously, we have shown that 27-OH mediates the negative effects of dietary cholesterol on several brain function related to cognition impairment [36]. Here, we explore whether the effects observed on S100A8 levels in the HFD mice may also be mediated by 27-OH. In a mouse model overexpressing the human CYP27a1 gene (CYP27Tg), having 5–6 times higher levels of 27-OH than WT animals, the level of S100A8 expression is higher in the hippocampus as shown by immunostaining (Fig. 2A and B) and by qPCR (Fig. 2C), especially in the pyramidal layers of CA1 and CA3 (Fig. 2D and E). When measured by western blot, the expression of RAGE was also increased compared to WT animals (Fig. 2F).

To confirm that the effects seen in the CYP27Tg mice are the effect of increased 27-OH, we injected 27-OH intracerebroventricular (ICV) into the lateral ventricle of WT mice at a concentration of 10 μM in artificial cerebrospinal fluid (27-OH aCSF). These mice exhibited in addition to the similar increase in the RNA expression of S100A8 (Fig. 3A) higher protein levels (Fig. 3B). As shown in Fig. 3C, RAGE protein levels were elevated in this acute model similarly to CYP27Tg mice.

Astrocytes Upregulate S100A8 and RAGE Expressions in the Presence of High 27-OH Levels

Primary rat astrocytic cultures were treated with 27-OH (1 μM, 24 h). Astrocytes produced a significant increase in S100A8 mRNA expression (Fig. 4A). RAGE mRNA (Fig. 4B) and protein (Fig. 4C) levels were increased likewise. In addition, confocal image analysis of these glial cultures treated with 27-OH (1 μM, 24 h) corroborated these results showing apparent increases in S100A8 and RAGE immunoreactivities, in addition to their colocalization (Fig. 4D).

27-OH-Induced RAGE Upregulation in Astrocytes Are Mediated by RXRγ

To decipher the possible mechanism through which 27-OH increases S100A8 and RAGE in astrocytes, we tested the role of the RXRγ, which we previously found mediates detrimental effects of 27-OH on neuron function [37, 38]. RXRγ is also expressed in hippocampal astrocytes, has been implicated in regulation of cholesterol metabolism, and has been suggested previously as a pharmacological target for AD [39–41]. Therefore, we decided to probe RXRγ as a potential mediator of the effects of 27-OH on RAGE expression in astrocytes. RXRγ was knocked down in astrocytes using siRNA and treatments with 27-OH. As seen by immunohistochemistry in Fig. 5A, the effect of high 27-OH on RAGE protein levels in astrocytes was decreased when combined with the RXRγ knockdown. Likewise, RXRγ knockdown blocked the 27-OH-induced RAGE increase of protein levels (Fig. 5B), as well as mRNA levels (Fig. 5C), with a knockdown efficiency of RXRγ of around 80% of control levels (Fig. 5D).

27-OH-Induced RAGE Increase in Neurons Is Mediated by RXRγ and Not by Direct LXRβ Activation

To test if high 27-OH levels were affecting RAGE expression in neurons, we used rat primary cortico-hippocampal cultures. When mature neurons were treated with 27-OH 1 μM for 24 h, we observed again an increase in RAGE protein levels compared to vehicle (Fig. 6A). Additionally, treatments with recombinant murine S100A8 12.5 μg/ml for 24 h showed significant increased RAGE protein levels (Fig. 6B). We previously reported 27-OH induces overexpression of RXRγ in neurons during differentiation; here, we treated neurons after 10 DIV for 24 h with 1 μM of 27-OH, and we found no change of RXRγ levels by western blot (Fig. 6C) (P = 0.057). When we knocked down RXRγ using siRNA, we found that RAGE increase with 27-OH was prevented (Fig. 6D). When LXRβ were blocked using 22(S)-OH treatments, RAGE increase is not prevented in the presence of high 27-OH levels (Fig. S4), which suggest LXRβ activation does not directly induces RAGE expression. Treatments with high 27-OH levels did not induce significant changes on the total levels of NFκ-B (Fig. S6A) in a similar way as S100A8 did (Fig. S6B); nevertheless, NFκ-B nuclear translocation was observed in the human neuroblastoma cell line SH-SY5Y (Fig. 6C).
Here, we report that excessive 27-OH triggers an alarmin response involving S100A8 and its receptor RAGE in both neurons and astrocytes, in vivo and in vitro. These results are consistent to the hypothesis proposing that 27-OH mediates detrimental effects of high-cholesterol in the plasma over the central nervous system (CNS), as shown by our experiments with HFD mice and in congruence with previous works from our group [15, 16, 34, 38]. While more evidence exists of the effect of 27-OH in neurons, our findings propose an astrocytic response to 27-OH involving the S100A8 alarmin.

In the periphery, S100A8 is involved in pathological cascades in multiple diseases such as rheumatoid arthritis [42], systemic erythematosus lupus [43], and cancer [44]. In the CNS, S100A8 is related to neurodegenerative diseases such as AD, where the expression of S100A8 is twofold higher in the hippocampi of AD patients compared to that of non-demented cases [45]. The same is suspected to happen in other neurodegenerative diseases like postoperative
cognitive dysfunction [46] and through autophagy alterations in Parkinson’s disease [47]. Moreover, treatment with Aβ increased the expression of S100A8 in different paradigms of glial cultures: by 30-fold in microglia chronic treatment after oligomeric Aβ increased the expression of S100A8 [48] and by twofold in astrocytes after Aβ42 incubation for only 24 h [23]. Previously, we also observed that S100A8 treatments increased the levels of Aβ42 suggesting a positive feedback between both their productions [23].

The intracellular colocalization of RAGE and S100A8 in...
cultured astrocytes shown in our work suggest a possible response to acute 27-OH treatments through internalization, while we have seen extracellular accumulation of S100A8 aggregates in CYP27Tg brains (data not shown); this could suggest that vesicular traffic would be important in the regulation of S100A8/RAGE signaling, and further experiments should be done to explore this avenue.

Our results show that in vivo, both CYP27Tg and the ICV27-OH mouse models increased their levels of S100A8 and RAGE in the brain as a response to excessive 27-OH levels. RAGE expression in the CNS promotes neurite outgrowth and neuronal differentiation [26] and participates in repairing injured nerves [49]. However, chronic RAGE stimulation affects neuronal function promoting both Tau phosphorylation and Aβ production, which would result in synaptic dysfunction and neurodegeneration [50]. Furthermore, the hippocampus of AD patients shows enhanced expressions of RAGE, Aβ, and advanced glycation end-products (AGE) as S100A8 [51]. Indeed, the increase in RAGE levels found in AD was shown in neurons, astrocytes, microglia, and endothelial cells [52, 53], and it is suggested to contribute to mechanism of AD pathogenesis such as oxidative stress, inflammation, neuronal dysfunction, and impairment of short-term memory [54–56].

Data from single-cell sequencing shows that S100A8 is not expressed by hippocampal neurons (Figure S3); however, it is prominently expressed in the mouse brain [57], so it must be in glial cells mediating the alarmin response such as astrocytes, as seen here by immunocytochemistry. This can be further confirmed consulting AD-oriented databases on single-cell expression such as scREAD, which shows microglia and astrocyte overexpressing S100A8 compared to WT mice in several datasets [58]. Given the low expression of neuronal S100A8, the effects of 27-OH over alarmin signaling in neurons is minimal; nevertheless, the induction of S100A8 and RAGE on astrocytes possibly contributes significantly to sterile inflammation. Together with other known neuronal effects [38, 59], high 27-OH levels in the brain can be detrimental for overall brain function due to several cascades that might potentiate between them. In this regard, patients with hereditary spastic paraplegia type 5A (SPG5) have very high 27-OH levels in their brain due to a mutation in the gene CYP7B1 encoding oxysterol-7α-hydroxylase [60]. While 27-OH has been found to be neurotoxic, SPG5 patients do not show significant neurodegeneration, which suggest that the interaction between different brain cell types could produce additional metabolites that could play a neuroprotective effect. On the other hand, macrophage activation induces a significant elevation of 25-OH in plasma upon activation [61], but whether this can be translated to microglial activation remains unknown to us. Also, since the CYP27Tg model has a normal CYP7B1 gene; it is possible that some of the in vivo effects here described could be mediated by intermediates of 27-OH.
metabolism like cholestenoic acids or 25-OH, since 27-OH has a rapid catabolism in the brain [62].

We previously found RXRγ is a mediator of 27-OH detrimental effects in neurons [38]; however, whether RXRγ played a role in astrocytes was unknown. siRNA silencing of RXRγ eliminated the 27-OH-induced increase of RAGE levels in astrocytes as seen by immunohistochemistry, western blot, and qPCR. RXRγ is a nuclear receptor that dimerizes with LXR and mediates transcription of genes involved in cholesterol and lipid metabolism [63–66]. Broad LXR blocking in astrocytes did not prevent RAGE increase mediated by 27-OH (Fig. S5). It is possible that 27-OH binds directly to RXRγ or promotes its dimerization with LXR or another nuclear receptor such as
RORα, which have been shown to bind oxysterols [67]. We showed that a similar mechanism regulating RAGE expression is present in neurons, since knockdown of RXRγ prevented 27-OH-induced RAGE expression at the mRNA level. Also, 27-OH induction of RAGE in primary neurons was independent of the presence of S100A8, meaning that high levels of 27-OH can sensitize neurons to alarmin signaling by increasing the amount of RAGE receptors before inflammation takes place (Fig. 7). This becomes evident when treating a human neuroblastoma cell line with high levels of 27-OH, which induces nuclear

**Fig. 6** 27-OH-induced RAGE increase in neurons. **A** Western blots from rat primary neurons treated with 27-OH (1 μM, 24 h) showing protein levels of RAGE (Vehicle mean = 1.0, SEM = 0.08, n = 8 wells; 27-OH mean = 1.34, SEM = 0.09, n = 8 wells. Unpaired t test P = 0.01). **B** Western blots from rat primary cultures treated with S100A8 (12.5 μg/ml, 24 h) showing protein levels of RAGE (Vehicle mean = 1.0, SEM = 0.08, n = 12 wells; 27-OH mean = 1.39, SEM = 0.13, n = 12 wells. Unpaired t test P = 0.02). **C** Western blots from rat primary neurons treated with 27-OH (1 μM, 24 h) showing protein levels of RXRγ (Vehicle mean = 1.0, SEM = 0.08, n = 8 wells; 27-OH mean = 1.34, SEM = 0.09, n = 8 wells. Unpaired t test P = 0.053) and **D** mRNA levels of RXRγ were diminished in the RXRγ-knockdown primary neurons treated with 27-OH (Control mean = 0.96, SEM = 0.1247, n = 4 wells; 27-OH mean = 2.007, SEM = 0.26, n = 6 wells; iRXRγ mean = 0.12). SEM = 0.056, n = 4 wells; iRXRγ + 27-OH mean = 0.58, SEM = 0.04, n = 4 wells. ANOVA P < 0.0001. Tukey’s multiple comparisons (**) P = 0.005; (*** P = 0.002), and a similar effect was found on RAGE mRNA expression (Control mean = 1.057, SEM = 0.033, n = 4 wells; 27-OH mean = 1.54, SEM = 0.101, n = 4 wells; iRXRγ mean = 0.29, SEM = 0.035, n = 4 wells; iRXRγ + 27-OH mean = 0.59, SEM = 0.35, n = 4 wells. ANOVA P = 0.0003. Tukey’s multiple comparisons (**) P = 0.0045)
translocation of NFk-B (Fig. S5). Finally, we propose that the effect of 27-OH over neuronal alarmin cascades can take place in humans since similar effects are found on human neuroblastoma cells (Fig. S1 and Fig. S5).

Conclusions

Our data supports the notion that high levels of peripheral cholesterol generate in turn increased 27-OH levels and enhance an inflammatory signaling cascade in the brain. HFD and excessive 27-OH result in S100A8 accumulation and increased RAGE expression in neurons and astrocytes and therefore enhance alarmin cascades mediated by RXRγ [20, 23]. These results place 27-OH as a mediator of the pathological mechanisms linking hypercholesterolemia and sterile inflammation in the brain, with potential implication in the pathophysiology of AD and other neurodegenerative diseases.

Abbreviations  AD: Alzheimer’s disease; APOEε4: Apolipoprotein E, allele epsilon 4; ApoJ: Clusterin; BBB: Blood–brain barrier; 27-OH: 27-Hydroxycholesterol; CYP27Tg: CYP27A1 overexpressor; CSF: Cerebrospinal fluid; RAGE: Receptor for advanced glycation end product; RXRγ: Retinoid X receptor gamma; HFD: High-fat/high-cholesterol diet; WT-HFD: Wild-type mice (WT) fed with HFD; WT-ND: Wild-type mice (WT) fed with normal diet; CA: Corpora amylacea; ICV: Intracerebroventricular injections; aCSF: Artificial cerebrospinal fluid; CNS: Central nervous system; HDL: High-density lipoprotein; NFk-B: Nuclear factor kappa-light-chain-enhancer of activated B cells; SPG5: Hereditary spastic paraplegia type 5A

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s12035-021-02521-8.

Acknowledgements  The imaging for this study was performed at the Live Cell Imaging Facility, Karolinska Institutet, Sweden, supported by grants from the Knut and Alice Wallenberg Foundation, the Swedish Research Council, the Centre for Innovative Medicine, and the Jonas Center at the Royal Institute of Technology, Sweden.

Author Contribution  Conceptualization, A. C.-M., I. B., and E. P.; methodology, J. G., A. C.-M., E. P., R. L.-V., M. L., and M.-A.-M. I.; investigation, M. A.-M. I., M. L., E. P., R. L.-V., L. M., P. R.-R., S. M., and P. M.-S.; S100A8 protein production and purification, C. G. and M. A. R.; formal analysis, M.-A.-M. I., M. L., E. P., R. L.-V., and L. M.; writing — original draft, M.-A.-M. I., R. L.-V., M. L., and A. C.-M.; writing — review and editing, all authors; funding acquisition, A. C.-M., M.-A.-M. I., R. L.-V., I. B., M. L., S. M., and E. P. All authors made substantial contributions to the manuscript. All authors read and approved the submitted manuscript.

Funding  Open access funding provided by Karolinska Institute. This research was supported by the following Swedish foundations: Swedish Brain Power, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, Strategic Neuroscience Program, Margaretha af Ugglas Foundation, Gun och Bertil Stohnes Stiftelse, Karolinska Institutet fund
for geriatric research, Stiftelsen Gamla Tjänarinnor, Demensfonden, Lindhés Advokatbyrå, Hjärnfonden, and Alzheimerfonden. R. L.-V. was financially supported by Mexico’s National Council for Science and Technology (CONACYT) CVU, 209252, and by Olle Enqvist Foundation grant no. 2014/778. Ramon Areces Foundation, Spain, supported E. P., EMBO Long-Term Fellowship (ALTF 696–2013), the SSMF postdoctoral fellowship, and Juan de la Cierva-Incorporación. (ICI-2016–27,658) supported P. M.-S.

Data Availability Data for this work is archived and publicly available upon request to the corresponding authors, as well as at the Karolinska Institutet repository and the Swedish National Archive.

Code Availability Software used in this work is commercially available. No custom coding was done for this work.

Declarations

Ethics Approval All experimental procedures with animals were conducted following European relevant guidelines and regulations and were approved by the Swedish Board of Agriculture (ethical permits ID S33-13, extension 57–15 and 4884/2019).

Consent to Participate Not applicable. This work does not include human patient’s samples.

Consent for Publication Not applicable. This work does not have human patient’s samples.

Competing Interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Anstey KJ, Ashby-Mitchell K, Peters R (2017) Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis 56(1):215–228
2. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16(5):343–354
3. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B et al (2008) Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12(6B):2762–2771
4. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J et al (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68(10):751–756
5. Kivipelto M (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322(7300):1447–1451
6. Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123):921–923
7. Harold D, Abrahm R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10):1088–1093
8. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM et al (2011) Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD31 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435
9. Kivipelto M, Helkala E-L, Laakso MP, Hänninen T, Hallikainen M, Alhainen K et al (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322(7300):1447–1451
10. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 68(11):1385–92
11. Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA (2008) Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 25(3):233–237
12. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer’s disease: the cholesterol connection. Nat Neurosci 6(4):345–351
13. Bjorkhem I, Cedeño-Minguez A, Leoni V, Meaney S (2009) Oxyesters and neurodegenerative diseases. Mol Aspects Med 30(3):171–179
14. Mateos L, Akterin S, Gil-Bea FJ, Spulber S, Rahman A, Bjorkhem I et al (2009) Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol 19(1):69–80
15. Ismail MA, Mateos L, Maioli S, Merino-Serras P, Ali Z, Lodeiro M et al (2017) 27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. J Exp Med 214(3):699–717
16. Heverin M, Maioli S, Pham T, Mateos L, Camporeesi E, Ali Z et al (2015) 27-Hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice. Behav Brain Res 278:356–359
17. Umetani M, Ghosh P, Ishikawa T, Umetani J, Ahmed M, Mineo C et al (2014) The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab 21(1):172–182
18. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L et al (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J Lipid Res 45(1):186–193
19. Calsolaro V, Edson P (2016) Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement 12(6):719–732
20. Vogt T, Stratis A, Wixler V, Voiler T, Thurainayagam S, Jorch SK et al (2018) Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation. J Clin Investig 128(5):1852–1866
21. Shepherd CE, Goyette J, Uitter V, Rahimi F, Yang Z, Geczy CL et al (2006) Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging 27(11):1554–1563
22. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T et al (2015)
In hippocampal neurons. Cereb Cortex 29(1):429–446

24. Hoy M, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH et al (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40(16):1203–1211

25. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H (2000) Coregulation of neurite outgrowth and cell survival by amyphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275(51):40096–40105

26. Yan SF, Yan SD, Ramasamy R, Schmidt AM (2009) Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 41(6):408–422

27. Meir K, Kitsberg D, Alkalay I, Szafer F, Rosen H, Shpitzen S et al (2002) Human sterol 27-hydroxylase (CYP27) overexpressor transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. J Biol Chem 277(37):34036–41

28. Cedazo-Minguez A, Hamker U, Meske V, Veh RW, Hellweg R, Jacobi C et al (2001) Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures. Neuroscience 105(3):651–61

29. Brophy MB, Hayden JA, Nolan EM (2012) Calcium ion gradients modulate the zinc affinity and antibacterial activity of human calprotectin. J Am Chem Soc 134(43):18089–18100

30. Hagmeyer S, Romão MA, Cristóstomo JS, Vilella A, Zoli M, Gomes CM, et al. Distribution and relative abundance of S100 proteins in the brain of the APP23 Alzheimer’s disease model mice. Front Neurosci. 2019;13(640).

31. Botelho HM, Fritz G, Gomes CM (2021) Analysis of S100 oligomers and amyloids. In: Sigurdsson EM, Calero M, Gassett M, editors. Amyloid proteins: methods and protocols. Methods in Molecular Biology. Springer Science+Business Media, New York

32. Mateos L, Ismail MA, Gil-Bea FJ, Schule R, Schols L, Heverin M et al (2011) Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism. J Biol Chem 286(29):25754–25758

33. Maioi S, Puerta E, Merino-Serrais P, Fusari L, Gil-Bea F, Rimondini R et al (2012) Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice. J Alzheimer’s Dis 32(2):341–355

34. Hoyaux D, Decaestecker C, Heizmann CW, Vogl T, Schaefer BW, Salmon I et al (2000) S100 proteins in corpora amylacea from normal human brain. Brain Res 867(1–2):280–288

35. Heverin M, Maioi S, Pham T, Mateos L, Camonen E, Ali Z et al (2015) 27-Hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice. Behav Brain Res 278:356–359

36. Baranowski M (2008) Biological role of liver X receptors. J Physiol Pharmacol 59(Suppl 7):31–55

37. Merino-Serrais P, Loera-Valencia R, Rodriguez-Rodriguez P, Parada-Fernandez C, Ismail MA, Maioi S et al (2019) 27-Hydroxycholesterol induces aberrant morphology and synaptic dysfunction in hippocampal neurons. Cereb Cortex 29(1):429–446

38. Repa JJ, Turdley SD, Lobaccaro JA, Medina J, Li L, Lustig K et al (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289(5484):1524–1529

39. Dheer Y, Chitranshi N, Gupta V, Abbasi M, Mirzaei M, You Y et al (2018) Bexarotene modulates retinoid-X-receptor expression and is protective against neurotoxic endoplasmic reticulum stress response and apoptotic pathway activation. Mol Neurobiol 55(12):9043–9056

40. Zeisel A, Munoz-Manchado AB, Codeluppi S, Lonnerberg P, La Manno G, Jureus A et al (2015) Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347(6226):1138–42

41. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H et al (2006) The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 8(3):R69

42. Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G (2009) Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 36(10):2190–2194

43. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M et al (2008) S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83(6):1484–1492

44. Lue LF, Kuo YM, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol 41(2–3):115–128

45. Lu SM, Yu CJ, Liu YH, Dong HQ, Zhang X, Zhang SS et al (2015) S100A8 contributes to postoperative cognitive dysfunction in mice undergoing tibial fracture surgery by activating the TLR4/MyD88 pathway. Brain Behav Immun 44:221–234

46. Ghavami S, Eshraghi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ et al (2010) S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves NBI3P. Cell Res 20(3):314–331

47. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE (2006) Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 79(3):596–610

48. Rong LL, Yan SF, Wendi T, Hans D, Pachydaki S, Bucciarelli LG et al (2004) RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J 18(15):1818–1825

49. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ (2012) AGES induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 33(7):1400–1410

50. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37(1):67–76

51. Sasaki N, Toki S, Chouei H, Saito T, Nakano N, Hayashi Y et al (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res 888(2):256–262

52. Miller MC, Tavares R, Johanson CE, Hovanessian V, Donahue JE, Gonzalez L et al (2008) Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease. Brain Res 1230:273–280

53. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D et al (2010) RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 24(4):1043–1055
55. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D et al (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23(20):4096–4105
56. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM et al (2008) Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28(13):3521–3530
57. Hagmeyer S, Romao MA, Cristovao JS, Vilella A, Zoli M, Gomes CM et al (2019) Distribution and relative abundance of S100 proteins in the brain of the APP23 Alzheimer’s disease model mice. Front Neurosci 13:640
58. Jiang J, Wang C, Qi R, Fu H, Ma Q (2020) scREAD: A single-cell RNA-Seq database for Alzheimer’s disease. iScience 23(11):944–951
59. Loera-Valencia R, Vazquez-Juarez E, Munoz A, Gerenu G, Gomez-Galan M, Lindskog M et al (2021) High levels of 27-hydroxycholesterol results in synaptic plasticity alterations in the hippocampus. Sci Rep 11(1):3736
60. Schols L, Rattay TW, Martus P, Meisner C, Baets J, Fischer I et al (2017) Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. Brain 140(12):3112–3127
61. Diczfalusy U (2013) On the formation and possible biological role of 25-hydroxycholesterol. Biochimie 95(3):455–460
62. Meaney S, Heverin M, Panzenboeck U, Ekstrom L, Axelsson M, Andersson U et al (2007) Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7α-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res 48(4):944–951
63. Wang H, Chu W, Hemphill C, Hasstedt SJ, Elbein SC (2002) Mutation screening and association of human retinoid X receptor gamma variant with lipid levels in familial type 2 diabetes. Mol Genet Metab 76(1):14–22
64. Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsuchida M, Takata M et al (2007) High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 27(4):923–928
65. Zhao C, Dahlman-Wright K (2010) Liver X receptor in cholesterol metabolism. J Endocrinol 204(3):233–240
66. Fan H, Dong W, Li Q, Zou X, Zhang Y, Wang J et al (2015) Ajuba Preferentially binds LXRalpha/RXRgamma heterodimer to enhance LXR target gene expression in liver cells. Mol Endocrinol 29(11):1608–1618
67. Wada T, Kang HS, Angers M, Gong H, Bhatia S, Khadem S et al (2008) Identification of oxysterol 7alpha-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor alpha (RORa) target gene and a functional cross-talk between RORa and liver X receptor (NR1H3). Mol Pharmacol 73(3):891–899

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Raúl Loera-Valencia1 · Muhammad-Al-Mustafa Ismail1 · Julen Goikolea1 · Maria Lodeiro1 · Laura Mateos1 · Ingemar Björkhem2 · Elena Puerta1,3 · Mariana A. Romão4,5 · Cláudio M. Gomes4,5 · Paula Merino-Serrais1,6,7 · Silvia Maioli1 · Angel Cedazo-Minguez1

Molecular Neurobiology (2021) 58:6063–6076